Get the Stockscreener App
1.43
1.06%
0.02
Metagenomi Therapeutics Inc stock is traded at $1.43, with a volume of 48,931.
It is up +1.06% in the last 24 hours and up +4.78% over the past month.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
See More
Previous Close:
$1.41
Open:
$1.43
24h Volume:
48,931
Relative Volume:
0.22
Market Cap:
$53.84M
Revenue:
$25.21M
Net Income/Loss:
$-87.87M
P/E Ratio:
-0.6067
EPS:
-2.357
Net Cash Flow:
$-89.47M
1W Performance:
+5.56%
1M Performance:
+4.78%
6M Performance:
-35.81%
1Y Performance:
-1.38%
1-Day Range:
$1.3901
$1.45
1-Week Range:
$1.33
$1.45
52-Week Range:
$1.25
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
Name
Metagenomi Therapeutics Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
1.43 | 53.08M | 25.21M | -87.87M | -89.47M | -2.357 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.53 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.51 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.06 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.37 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Therapeutics Inc Stock (MGX) Latest News
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
SEC Form DEF 14A filed by Metagenomi Therapeutics Inc. - Quantisnow
[DEF 14A] Metagenomi Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
MGX Price Today: Metagenomi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
MGX Stock Price, Quote & Chart | METAGENOMI THERAPEUTICS INC (NASDAQ:MGX) - ChartMill
Metagenomi Therapeutics (MGX) Stock: Sentiment Analysis (Weakens) 2026-04-22Large Cap Trends - UBND thành phố Hải Phòng
MGX Financials: Income Statement, Balance Sheet & Cash Flow | Metagenomi Therapeutics, Inc - Stock Titan
A smaller gene editor cut Atxn2 protein 64% in mice, Metagenomi says - Stock Titan
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Eastern Progress
What is the valuation of Metagenomi Therapeutics (MGX) Stock | Price at $1.39, Up 0.72%Portfolio Management - UBND thành phố Hải Phòng
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
MGX: Metagenomi Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
Metagenomi Can’t Ax IPO Investor Suit Over Moderna Partnership - Bloomberg Law News
If You Invested $1,000 in Metagenomi Therapeutics, Inc (MGX) - Stock Titan
Metagenomi Therapeutics Fiscal Results: Q4 Loss of $22.5M, Annual Loss $87.9MNews and Statistics - IndexBox
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics: Q4 Earnings Snapshot - kens5.com
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results - Bitget
Metagenomi Therapeutics Q4 Earnings Assessment - Benzinga
MGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MGX Technical Analysis & Stock Price Forecast - Intellectia AI
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference - The Manila Times
Metagenomi Therapeutics, Inc. CEO Jian Irish to Speak at 46th Annual TD Cowen Healthcare Conference - Quiver Quantitative
Gene-editing firm Metagenomi CEO in TD Cowen fireside chat - Stock Titan
MGXMetagenomi Therapeutics, Inc Latest Stock News & Market Updates - Stock Titan
Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Head to Head Analysis: Acusphere (OTCMKTS:ACUS) and Metagenomi (NASDAQ:MGX) - Defense World
Xeris Biopharma (NASDAQ:XERS) and Metagenomi (NASDAQ:MGX) Critical Comparison - Defense World
Metagenomi (NASDAQ:MGX) and UCB (OTCMKTS:UCBJY) Critical Survey - Defense World
These two noteworthy penny stocks can do wonders! Here's more insights into Alto Ingredients, Metagenomi and others - MSN
Aug Sentiment: Why Metagenomi Inc stock could benefit from AI revolutionAnalyst Upgrade & Daily Volume Surge Trade Alerts - moha.gov.vn
Resistance Check: Should I add Metagenomi Inc stock to my portfolioJuly 2025 Catalysts & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Metagenomi changes name, advances hemophilia A gene therapy program By Investing.com - Investing.com Nigeria
Metagenomi advances gene editing therapies into 2025 - MSN
Metagenomi changes name, advances hemophilia A gene therapy program - Investing.com
Metagenomi Therapeutics Rebrands to Emphasize Therapeutic Focus - TipRanks
Metagenomi to submit IND in Q4 2026 to advance MGX-001 into first human studies - TipRanks
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook - The Manila Times
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights ... - bdtonline.com
Gainers Report: Is Metagenomi Inc stock dividend yield sustainableFed Meeting & Weekly Top Performers Watchlists - moha.gov.vn
Is Metagenomi Inc. stock dividend yield sustainableWide Width Options & HOKA model picks for your routine - ulpravda.ru
Operating cash flow per share of Metagenomi, Inc. – NASDAQ:MGX - TradingView — Track All Markets
VIX Spike: Is Metagenomi Inc. stock dividend yield sustainableTrend Reversal & Expert Curated Trade Setups - Улправда
Patterns Watch: Is Metagenomi Inc. stock undervalued vs historical averages2025 Historical Comparison & Consistent Profit Trading Strategies - Улправда
Is Metagenomi Inc. stock positioned well for digital economy2025 Stock Rankings & AI Forecasted Entry and Exit Points - Улправда
Is Metagenomi Inc. stock a defensive play in 2025Earnings Miss & Weekly High Momentum Picks - Улправда
Will Metagenomi Inc. stock attract ESG investors2025 Short Interest & Free AI Powered Buy and Sell Recommendations - Улправда
How interest rate cuts could boost Metagenomi Inc. stock2025 Trading Volume Trends & High Accuracy Investment Entry Signals - ulpravda.ru
Market Overview: Is Metagenomi Inc. stock supported by innovation pipelineWeekly Profit Summary & Expert-Curated Trade Recommendations - ulpravda.ru
Is Metagenomi Inc. stock in correction or buying zoneWeekly Investment Report & Capital Efficiency Focused Ideas - Улправда
Oklahoma City NewsThe OklahomanMetagenomi, Inc.Common Stock (Nasdaq:MGX) Detailed Stock Data - FinancialContent
Metagenomi Therapeutics Inc Stock (MGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):